**Core Concept**
Ulcerative colitis is a type of inflammatory bowel disease characterized by chronic inflammation and ulceration of the colonic mucosa. The mainstay of treatment involves strategies to reduce inflammation, induce and maintain remission, and improve quality of life.

**Why the Correct Answer is Right**
The correct answer is based on the concept of "top-down" treatment, which involves the use of potent anti-inflammatory agents to induce remission in patients with moderate to severe disease. For patients with mild ulcerative colitis, the initial treatment is often based on the "top-down" approach, which includes the use of aminosalicylates (5-ASAs) or corticosteroids to reduce inflammation. The use of immunomodulators or biologics is typically reserved for patients who do not respond to initial therapy.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because aminosalicylates are not typically used as first-line therapy in patients with mild ulcerative colitis. However, they may be used in patients with mild to moderate disease who do not respond to initial therapy.
* **Option B:** This option is incorrect because the use of corticosteroids is typically reserved for patients with moderate to severe disease who do not respond to initial therapy.
* **Option C:** This option is incorrect because the use of immunomodulators or biologics is typically reserved for patients who do not respond to initial therapy.

**Clinical Pearl / High-Yield Fact**
Aminosalicylates, such as mesalamine, are effective in reducing inflammation in patients with mild to moderate ulcerative colitis. They work by inhibiting the production of pro-inflammatory cytokines and reducing the adhesion of leukocytes to the colonic mucosa.

**Correct Answer: A. 5-aminosalicylic acid (5-ASA) or mesalamine**